Structural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition

Chagas disease, which was once thought to be confined to endemic regions of Latin America, has now gone global, becoming a new worldwide challenge with no cure available. The disease is caused by the protozoan parasite Trypanosoma cruzi, which depends on the production of endogenous sterols, and therefore can be blocked by sterol 14α-demethylase (CYP51) inhibitors. Here we explore the spectral binding parameters, inhibitory effects on T. cruzi CYP51 activity, and antiparasitic potencies of a new set of β-phenyl imidazoles. Comparative structural characterization of the T. cruzi CYP51 complexes with the three most potent inhibitors reveals two opposite binding modes of the compounds ((R)-6, EC50 = 1.2 nM, vs (S)-2/(S)-3, EC50 = 1.0/5.5 nM) and suggests the entrance into the CYP51 substrate access channel and the heme propionate-supporting ceiling of the binding cavity as two distinct areas of the protein that enhance molecular recognition and therefore could be used for the development of more effective antiparasitic drugs.

[1]  M. Waterman,et al.  Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human Infections*♦ , 2009, The Journal of Biological Chemistry.

[2]  M. Gelb,et al.  A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Durvasula,et al.  Globalization of Chagas Disease: A Growing Concern in Nonendemic Countries , 2012 .

[4]  R. Isturiz,et al.  Chagas Disease , 2021, Neglected Tropical Diseases.

[5]  M. Gelb,et al.  The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. , 2005, Journal of medicinal chemistry.

[6]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[7]  S. Montgomery,et al.  Trypanosoma cruzi and Chagas' Disease in the United States , 2011, Clinical Microbiology Reviews.

[8]  M. J. Uddin,et al.  Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. , 2009, Journal of medicinal chemistry.

[9]  J. Urbina,et al.  Ergosterol biosynthesis and drug development for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[10]  David M. Shackleford,et al.  Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib , 2012, Antimicrobial Agents and Chemotherapy.

[11]  M. Waterman,et al.  Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). , 2011, Advances in parasitology.

[12]  Mitch Leslie,et al.  Infectious diseases. Drug developers finally take aim at a neglected disease. , 2011, Science.

[13]  M. Waterman,et al.  Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. , 2007, Biochimica et biophysica acta.

[14]  M. Waterman,et al.  CYP51 from Trypanosoma cruzi , 2006, Journal of Biological Chemistry.

[15]  G. Lepesheva Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? , 2013, Expert opinion on drug discovery.

[16]  J. Clayton Chagas disease: pushing through the pipeline , 2010, Nature.

[17]  P. Hotez,et al.  Neglected Infections of Poverty in Texas and the Rest of the United States: Management and Treatment Options , 2012, Clinical pharmacology and therapeutics.

[18]  M. Waterman,et al.  Sterol 14α-Demethylase Cytochrome P450 (CYP51), a P450 in all Biological Kingdoms , 2007 .

[19]  M. Waterman,et al.  Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi* , 2010, The Journal of Biological Chemistry.

[20]  M. Chorilli,et al.  Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity. , 2014, Journal of medicinal chemistry.

[21]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[22]  M. Waterman,et al.  In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma cruzi , 2013, Antimicrobial Agents and Chemotherapy.

[23]  M. Waterman,et al.  VNI cures acute and chronic experimental Chagas disease. , 2013, The Journal of infectious diseases.

[24]  S. Pratap,et al.  Cellular Response to Trypanosoma cruzi Infection Induces Secretion of Defensin α-1, Which Damages the Flagellum, Neutralizes Trypanosome Motility, and Inhibits Infection , 2013, Infection and Immunity.

[25]  Paul W. Alexander,et al.  Complexes of Trypanosoma cruzi Sterol 14α-Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease , 2013, The Journal of Biological Chemistry.

[26]  M. Waterman,et al.  Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. , 2007, Chemistry & biology.

[27]  C. Bern Antitrypanosomal therapy for chronic Chagas' disease. , 2011, The New England journal of medicine.

[28]  M. Lima,et al.  Trypanosoma cruzi trypomastigote clones differentially express a parasite cell adhesion molecule. , 1989, Molecular and biochemical parasitology.

[29]  M. Waterman,et al.  Structural basis for conservation in the CYP51 family. , 2011, Biochimica et biophysica acta.

[30]  Peter J. Hotez,et al.  Neglected Infections of Poverty in the United States of America , 2008, PLoS neglected tropical diseases.

[31]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[32]  F. D. D'Auria,et al.  Synthesis and antifungal activity of a new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives. , 2012, European journal of medicinal chemistry.

[33]  C. Zamperini,et al.  New Promising Compounds with in Vitro Nanomolar Activity against Trypanosoma cruzi. , 2013, ACS medicinal chemistry letters.

[34]  M. Waterman,et al.  CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds. , 2012, International journal for parasitology. Drugs and drug resistance.